GoodRx Holdings (GDRX) Equity Average (2019 - 2026)

GoodRx Holdings has disclosed Equity Average across 8 years of filings, most recently posting $619.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $619.1 million, down 10.21% year-over-year; the trailing twelve-month figure through Mar 2026 was $619.1 million (down 10.21% YoY), and the FY2025 annual result was $670.5 million, down 9.8% from the prior year.
• Equity Average came in at $619.1 million for Q1 2026 at GoodRx Holdings, up from $608.5 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $888.3 million in Q3 2023 to a low of $608.5 million in Q4 2025.
• The 5-year median for Equity Average is $710.5 million (2024), against an average of $737.4 million.
• Across the five-year window, Equity Average rose 10.8% in 2022 and slipped 24.52% in 2024, its largest moves.
• GoodRx Holdings' Equity Average stood at $801.6 million in 2022, then increased by 2.5% to $821.6 million in 2023, then retreated by 13.52% to $710.5 million in 2024, then declined by 14.36% to $608.5 million in 2025, then advanced by 1.75% to $619.1 million in 2026.
• The last three Equity Average figures came in at $619.1 million (Q1 2026), $608.5 million (Q4 2025), and $621.9 million (Q3 2025), per Business Quant data.